Plasma and tissue levels of neuropeptide Y in experimental septic shock: Relation to hemodynamics, inflammation, oxidative stress, and hemofiltration

Artificial Organs

Volumn 35, Issue 6, 2011, Pages 625-633

  Kuncová, Jitka ^a   Sýkora, Roman ^a   Chvojka, Jiří ^a   Švíglerová, Jitka ^a   Štengl, Milan ^a   Kroužecký, Aleš ^a   Nalos, Lukáš ^a   Matějovič, Martin ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Hemodynamics; Hemofiltration; Inflammatory mediators; Neuropeptide Y; Septic shock

Indexed keywords

ARTIFICIAL ORGANS; BLOOD PRESSURE; BLOOD VESSELS; TISSUE;

CONTROL GROUPS; HAEMODYNAMICS; HEMOFILTRATION; INFLAMMATORY MEDIATORS; NEUROPEPTIDE Y; PLASMA CONCENTRATION; PLASMA LEVELS; SEPTIC SHOCKS; SYMPATHETIC NERVES; TISSUE LEVELS;

HEMODYNAMICS;

BIOLOGICAL MARKER; INTERLEUKIN 6; NEUROPEPTIDE Y; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY; HEART OUTPUT; HEART RATE; HEMODYNAMICS; HEMOFILTRATION; HUMAN; INFLAMMATION; MEAN ARTERIAL PRESSURE; NONHUMAN; OXIDATIVE STRESS; PERITONITIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEPTIC SHOCK; VASCULAR RESISTANCE;

SUS; SUS SCROFA DOMESTICA;

EID: 79958779436     PISSN: 0160564X     EISSN: 15251594     Source Type: Journal    
DOI: 10.1111/j.1525-1594.2010.01154.x     Document Type: Article

References (52)

1. Pedrazzini T, Pralong F, Grouzmann E. Neuropeptide Y: the universal soldier. Cell Mol Life Sci 2003;60:350-77.
2. Pernow J, Ohlén A, Hökfelt T, Nilsson O, Lundberg JM. Neuropeptide Y: presence in perivascular noradrenergic neurons and vasoconstrictor effects on skeletal muscle blood vessels in experimental animals and man. Regul Pept 1987;19:313-24.
3. Kennedy B, Shen GH, Ziegler MG. Neuropeptide Y-mediated pressor responses following high-frequency stimulation of the rat sympathetic nervous system. J Pharmacol Exp Ther 1997;281:291-6.
4. Ren LM, Furukawa Y, Karasawa Y, etal. Differential inhibition of neuropeptide Y on the chronotropic and inotropic responses to sympathetic and parasympathetic stimulation in the isolated, perfused dog atrium. J Pharmacol Exp Ther 1991;259:38-43.
5. Franco-Cereceda A, Lundberg JM, Dahlöf C. Neuropeptide Y and sympathetic control of heart contractility and coronary vascular tone. Acta Physiol Scand 1985;124:361-9.
6. Xiang H. Comparative aspects of the role of neuropeptide Y in the regulation of the vertebrate heart. Cardioscience 1994;5:209-13.
7. Bellinger DL, Millar BA, Perez S, etal. Sympathetic modulation of immunity: relevance to disease. Cell Immunol 2008;252:27-56.
8. Kulkarni-Narla A, Beitz AJ, Brown DR. Catecholaminergic, cholinergic and peptidergic innervation of gut-associated lymphoid tissue in porcine jejunum and ileum. Cell Tissue Res 1999;298:275-86.
9. Straub RH, Schaller T, Miller LE, etal. Neuropeptide Y cotransmission with norepinephrine in the sympathetic nerve-macrophage interplay. J Neurochem 2000;75:2464-71.
10. Bedoui S, Lechner S, Gebhardt T, etal. NPY modulates epinephrine-induced leukocytosis via Y-1 and Y-5 receptor activation in vivo: sympathetic co-transmission during leukocyte mobilization. J Neuroimmunol 2002;132:25-33.
11. Hernanz A, Tato E, De la Fuente M, de Miguel E, Arnalich F. Differential effects of gastrin-releasing peptide, neuropeptide Y, somatostatin and vasoactive intestinal peptide on interleukin-1 beta, interleukin-6 and tumor necrosis factor-alpha production by whole blood cells from healthy young and old subjects. J Neuroimmunol 1996;71:25-30.
12. Sung CP, Arleth AJ, Feuerstein GZ. Neuropeptide Y upregulates the adhesiveness of human endothelial cells for leukocytes. Circ Res 1991;68:314-8.
13. Dimitrijević M, Stanojević S, Vujić V, etal. Effect of neuropeptide Y on inflammatory paw edema in the rat: involvement of peripheral NPY Y1 and Y5 receptors and interaction with dipeptidyl-peptidase IV (CD26). J Neuroimmunol 2002;1291:35-42.
14. Shimaoka M, Park EJ. Advances in understanding sepsis. Eur J Anaesthesiol Suppl 2008;42:146-53.
15. Godin PJ, Buchman TG. Uncoupling of biologic oscillators: a complementary hypothesis concerning the pathogenesis of multiple organ dysfunction syndrome. Crit Care Med 1996;24:1107-16.
16. Bedoui S, Kawamura N, Straub RH, Pabst R, Yamamura T, von Hörsten S. Relevance of neuropeptide Y for the neuroimmune crosstalk. J Neuroimmunol 2003;134:1-11.
17. Pekárková I, Parara S, Holecek V, etal. Does exogenous melatonin influence the free radicals metabolism and pain sensation in rat? Physiol Res 2001;50:595-602.
18. Matejovic M, Krouzecky A, Martinkova V, etal. Selective inducible nitric oxide synthase inhibition during long-term hyperdynamic porcine bacteremia. Shock 2004;21:458-65.
19. Matejovic M, Krouzecky A, Martinkova V, etal. Effects of tempol, a free radical scavenger, on long-term hyperdynamic porcine bacteremia. Crit Care Med 2005;33:1057-63.
20. Arnalich F, Sánchez JF, Martínez M, etal. Changes in plasma concentrations of vasoactive neuropeptides in patients with sepsis and septic shock. Life Sci 1995;56:75-81.
21. Wang X, Jones SB, Zhou Z, Han C, Fiscus RR. Calcitonin gene-related peptide (CGRP) and neuropeptide Y (NPY) levels are elevated in plasma and decreased in vena cava during endotoxic shock in the rat. Circ Shock 1992;36:21-30.
22. Rudehill A, Olcén M, Sollevi A, Hamberger B, Lundberg JM. Release of neuropeptide Y upon haemorrhagic hypovolaemia in relation to vasoconstrictor effects in the pig. Acta Physiol Scand 1987;131:517-23.
23. Hauser GJ, Danchak MR, Colvin MP, etal. Circulating neuropeptide Y in humans: relation to changes in catecholamine levels and changes in hemodynamics. Neuropeptides 1996;30:159-65.
24. Zukowska-Grojec Z, Dayao EK, Karwatowska-Prokopczuk E, Hauser GJ, Doods HN. Stress-induced mesenteric vasoconstriction in rats is mediated by neuropeptide Y Y1 receptors. Am J Physiol 1996;270:H796-800.
25. Soop A, Albert J, Weitzberg E, Bengtsson A, Lundberg JN, Sollevi A. Complement activation, endothelin-1 and neuropeptide Y in relation to the cardiovascular response to endotoxin-induced systemic inflammation in healthy volunteers. Acta Anaesthesiol Scand 2004;48:74-81.
26. Watson JD, Sury MR, Corder R, etal. Plasma levels of neuropeptide tyrosine Y (NPY) are increased in human sepsis but are unchanged during canine endotoxin shock despite raised catecholamine concentrations. J Endocrinol 1988;116:421-6.
27. Evéquoz D, Waeber B, Corder R, Nussberger J, Gaillard R, Brunner HR. Markedly reduced blood pressure responsiveness in endotoxemic rats; reversal by neuropeptide Y. Life Sci 1987;41:2573-80.
28. Hauser GJ, Myers AK, Dayao EK, Zukowska-Grojec Z. Neuropeptide Y infusion improves hemodynamics and survival in rat endotoxic shock. Am J Physiol 1993;265:H1416-23.
29. Zukowska-Grojec Z. Neuropeptide Y. A novel sympathetic stress hormone and more. Ann N Y Acad Sci 1995;771:219-33.
30. Ericsson A, Hemsén A, Lundberg JM, Persson H. Detection of neuropeptide Y-like immunoreactivity and messenger RNA in rat platelets: the effects of vinblastine, reserpine, and dexamethasone on NPY expression in blood cells. Exp Cell Res 1991;192:604-11.
31. Lundberg JM, Franco-Cereceda A, Lacroix JS, Pernow J. Neuropeptide Y and sympathetic neurotransmission. Ann N Y Acad Sci 1990;611:166-74.
32. D'Hooge R, De Deyn PP, Verzwijvelen A, De Block J, De Potter WP. Storage and fast transport of noradrenaline, dopamine beta-hydroxylase and neuropeptide Y in dog sciatic nerve axons. Life Sci 1990;47:1851-9.
33. De la Fuente M, Bernaez I, Del Rio M, Hernanz A. Stimulation of murine peritoneal macrophage functions by neuropeptide Y and peptide YY. Involvement of protein kinase C. Immunology 1993;80:259-65.
34. Wheway J, Mackay CR, Newton RA, etal. A fundamental bimodal role for neuropeptide Y1 receptor in the immune system. J Exp Med 2005;202:1527-38.
35. Nair MP, Schwartz SA, Wu K, Kronfol Z. Effect of neuropeptide Y on natural killer activity of normal human lymphocytes. Brain Behav Immun 1993;7:70-7.
36. Kawamura N, Tamura H, Obana S, etal. Differential effects of neuropeptides on cytokine production by mouse helper T cell subsets. Neuroimmunomodulation 1998;5:9-15.
37. Medina S, Del Río M, Hernanz A, De la Fuente M. The NPY effects on murine leukocyte adherence and chemotaxis change with age. Adherent cell implication. Regul Pept 2000;95:35-45.
38. Bedoui S, Kuhlmann S, Nave H, Drube J, Pabst R, von Hörsten S. Differential effects of neuropeptide Y (NPY) on leukocyte subsets in the blood: mobilization of B-1-like B-lymphocytes and activated monocytes. J Neuroimmunol 2001;117:125-32.
39. Vanholder R, De Smet R, Glorieux G, etal. European Uremic Toxin Work Group (EUTox). Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int 2003;63:1934-43.
40. Clark WR, Hamburger RJ, Lysaght MJ. Effect of membrane composition and structure on solute removal and biocompatibility in hemodialysis. Kidney Int 1999;56:2005-15.
41. Honoré PM, Matson JR. Hemofiltration, adsorption, sieving and the challenge of sepsis therapy design. Crit Care 2002;6:394-6.
42. Leypoldt JK, Jaber BL, Lysaght MJ, McCarthy JT, Moran J. Kinetics and dosing predictions for daily haemofiltration. Nephrol Dial Transplant 2003;18:769-76.
43. Heering P, Morgera S, Schmitz FJ, etal. Cytokine removal and cardiovascular hemodynamics in septic patients with continuous venovenous hemofiltration. Intensive Care Med 1997;23:88-296.
44. Heering P, Grabensee B, Brause M. Cytokine removal in septic patients with continuous venovenous hemofiltration. Kidney Blood Press Res 2003;26:128-34.
45. Sykora R, Chvojka J, Krouzecky A, etal. High versus standard-volume haemofiltration in hyperdynamic porcine peritonitis: effects beyond haemodynamics? Intensive Care Med 2009;35:371-80.
46. Jiang HL, Xue WJ, Li DQ, etal. Influence of continuous veno-venous hemofiltration on the course of acute pancreatitis. World J Gastroenterol 2005;11:4815-21.
47. Goldfarb S, Golper TA. Proinflammatory cytokines and hemofiltration membranes. J Am Soc Nephrol 1994;5:228-32.
48. Kellum JA, Song M, Venkataraman R. Hemoadsorption removes tumor necrosis factor, interleukin-6, and interleukin-10, reduces nuclear factor-kappaB DNA binding, and improves short-term survival in lethal endotoxemia. Crit Care Med 2004;32:801-5.
49. Joannidis M. Continuous renal replacement therapy in sepsis and multisystem organ failure. Semin Dial 2009;22:160-4.
50. Morris MJ, Russell AE, Kapoor V, etal. Increases in plasma neuropeptide Y concentrations during sympathetic activation in man. J Auton Nerv Syst 1986;17:143-9.
51. Takiyyuddin MA, Brown MR, Dinh TQ, etal. Sympatho-adrenal secretion in humans: factors governing catecholamine and storage vesicle peptide co-release. J Auton Pharmacol 1994;14:187-200.
52. Schwarz H, Villiger PM, von Kempis J, Lotz M. Neuropeptide Y is an inducible gene in the human immune system. J Neuroimmunol 1994;51:53-61.